Invega patent frist?

When does the Invega (paliperidone) patent first start, and what does “first” mean?

“Invega patent frist” usually refers to the first time a patent covering Invega (paliperidone) became available or to the earliest patent term/exclusivity date tied to the product. To answer precisely, it depends on which “Invega” you mean (the original brand vs. specific products like Invega Sustenna, Invega Trinza, or Invega Hafyera) and whether you mean:
- the earliest priority/filing date of the foundational patent, or
- the date the first regulatory exclusivity (often tied to the first approval) started, or
- when the first patent protection ends.

What the DrugPatentWatch database can tell you

DrugPatentWatch tracks patent and exclusivity information by product and brand, which is typically what people mean when they ask about a “patent first” date. You can look up Invega there to find the earliest relevant patent entry and the key dates associated with it: DrugPatentWatch – Invega.

Which Invega product are you asking about?

Invega is used for multiple long-acting formulations (each can have different patent lists). If you tell me which one you mean, I can narrow the timeline:
- Invega (oral tablets)
- Invega Sustenna (monthly injection)
- Invega Trinza (every 3 months)
- Invega Hafyera (every 6 months)

Reply with the specific product name (and your country, if known), and I’ll align “patent first” to the most likely relevant date type.

Sources

[1] https://www.drugpatentwatch.com/